ClinicalTrials.gg
Enrolling by invitationNCT07941050Updated Nov 17, 2026

Effects of Synbiotic Supplementation on Adipose Tissue Factors in Obese Women Undergoing Sleeve Gastrectomy

An interventional study of Synbiotic Supplement and Placebo in Obesity, sponsored by Tehran University of Medical Sciences. Enrolling by invitation at 1 site in Iran. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Tehran University of Medical Sciences · Not applicable, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

Obesity is a complex, multifactorial disease driven by metabolic dysfunction, chronic low-grade inflammation, oxidative stress, and gut microbiota dysbiosis. The pathogenesis of obesity is closely linked to white adipose tissue (WAT) dysfunction, particularly the dysregulation of lipogenic and adipogenic pathways, leading to adipocyte hypertrophy and ectopic fat deposition. Although sleeve gastrectomy is a gold-standard intervention for severe obesity, a subset of patients experiences suboptimal long-term weight loss and cardiometabolic improvements, potentially due to persistent inflammation and metabolic resistance.

The gut-adipose axis has emerged as a critical therapeutic target. Modulation of the gut microbiome through synbiotic supplementation may alleviate metabolic endotoxemia and systemic inflammation, thereby improving energy homeostasis. However, the impact of presurgical synbiotic intervention on adipose tissue remodeling in patients undergoing sleeve gastrectomy remains largely unexplored.

This triple-blind, randomized controlled trial (RCT) aims to evaluate the efficacy of synbiotic supplementation in obese women candidates for sleeve gastrectomy. The objective is to investigate the effect of synbiotics on the expression of key lipogenic and adipogenic transcriptional factors (e.g., SREBP-1c, C/EBPα, PPARγ, LXRs) and rate-limiting enzymes (e.g, FAS, ACC) in white adipose tissue.

The study hypothesis is that presurgical synbiotic intervention will modulate adipose tissue function, thereby enhancing postoperative weight loss and improving metabolic profiles. The study aims to provide evidence for a potential therapeutic strategy to optimize clinical outcomes in bariatric patients by targeting the molecular mechanisms underlying adipose tissue expansion.

02

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Obesity
  • synbiotic
  • Adipose Tissue
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's planned enrollment of 50 is below the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Tehran University of Medical Sciences is the lead sponsor of 232 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria

Participants must meet all of the following criteria:

  1. Female candidates for sleeve gastrectomy.
  2. Age between 18 and 50 years, inclusive.
  3. (BMI) ≥40 kg/m² (morbid obesity).
  4. Willingness to participate in the study and provide . Exclusion Criteria

Participants will be excluded if any of the following criteria apply:

  1. Diabetes mellitus.
  2. Ischemic heart disease.
  3. Cognitive impairment that prevents understanding of the study procedures or provision of informed consent.
  4. Chronic gastrointestinal diseases, including inflammatory bowel disease, untreated active celiac disease, chronic pancreatitis, or a history of major intestinal surgery.
  5. Severe steatohepatitis, advanced hepatic fibrosis, liver cirrhosis, or hepatic insufficiency. Mild-to-moderate non-alcoholic fatty liver disease (NAFLD) will not be an exclusion criterion.
  6. Chronic kidney disease or renal impairment.
  7. .
  8. Use of agents, nonsteroidal anti-inflammatory drugs (NSAIDs), or insulin within one month before study initiation.
  9. Current tobacco use or illicit drug use.
  10. Untreated thyroid dysfunction.
  11. Concurrent participation in another interventional clinical trial.
  12. Psychiatric disorders, including schizophrenia or depression, or current use of psychiatric medications.
  13. Current or recent chemotherapy.
  14. Pregnancy or breastfeeding.
  15. Menopause.
  16. Antibiotic use within the previous three months.
  17. Use of probiotic supplements or regular consumption of probiotic-enriched foods, including probiotic yogurt, cheese, cakes, biscuits, or pasta, according to the study protocol.
  18. Excessive alcohol consumption, defined as ≥20 g of alcohol per day.
  19. Use of medications intended for weight loss or appetite suppression. Participant Discontinuation and Withdrawal Participants who discontinue participation during the 12-week intervention period for any reason, or who require treatment with medications prohibited by the study protocol, will discontinue the intervention and will be managed according to the study's prespecified withdrawal procedures.

Participants who consume less than 90% of the prescribed supplements during the intervention period will be classified as having inadequate adherence.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Synbiotic Intervention

    Participants will receive one sachet of synbiotic supplement daily for 12 weeks. Each sachet contains Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus plantarum, Streptococcus thermophilus, Bifidobacterium longum (1×10⁹ CFU/sachet total) and inulin. Supplements will be distributed monthly.

    Dietary Supplement: Synbiotic Supplement

  • Placebo comparator
    Placebo Control

    Participants will receive one sachet of placebo (containing cellulose) daily for 12 weeks. Supplements will be distributed monthly.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementSynbiotic Supplement

    In the intervention group, participants will receive one sachet of synbiotic supplement orally once daily for 12 weeks. Each sachet contains a combination of Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus plantarum, Streptococcus thermophilus, and Bifidobacterium longum, providing a total of 1 × 10⁹ colony-forming units, along with inulin as a prebiotic component.

  • Dietary supplementPlacebo

    In the placebo , participants will receive one sachet of placebo containing cellulose, identical in appearance, taste, and packaging to the active supplement to maintain blinding. Both interventions will be administered orally once daily for 12 weeks, with supplements dispensed monthly to support participant compliance and adherence throughout the study.

06

What researchers measure

Primary outcomes

  1. Fatty Acid Synthase (FAS) mRNA level and protein level in subcutaneous and abdominal adipose tissue

    Adipose tissue samples will be collected from obese women candidates for sleeve gastrectomy during surgery 12 weeks post-intervention. mRNA levels will be quantified using real-time quantitative PCR (qRT-PCR), and protein expression will be assessed by Western blot analysis.

    Time frame: 12 weeks after intervention

  2. Sterol Regulatory Element-Binding Protein-1c (SREBP) mRNA and protein levels in abdominal and subcutaneous adipose tissue

    Adipose tissue samples will be collected from obese women candidates for sleeve gastrectomy during surgery 12 weeks post-intervention. mRNA levels will be quantified using real-time quantitative PCR (qRT-PCR), and protein expression will be assessed by Western blot analysis

    Time frame: 12 weeks after intervention

  3. Acetyl-CoA carboxylase (ACC) mRNA and protein levels in subcutaneous and abdominal adipose tissue

    Adipose tissue samples will be collected from obese women candidates for sleeve gastrectomy during surgery 12 weeks post-intervention. mRNA levels will be quantified using real-time quantitative PCR (qRT-PCR), and protein expression will be assessed by Western blot analysis

    Time frame: 12 weeks after intervention

  4. Peroxisome proliferator-activated receptor gamma (PPAR-γ ) mRNA level in abdominal and subcutaneous adipose tissue

    Adipose tissue samples will be collected from obese women candidates for sleeve gastrectomy during surgery 12 weeks post-intervention. mRNA levels will be quantified using real-time quantitative PCR (qRT-PCR).

    Time frame: 12 weeks after intervention

  5. Peroxisome proliferator-activated receptor-γ coactivator 1-α (PGC-1α) mRNA level in abdominal and subcutaneous adipose tissue

    Adipose tissue samples will be collected from obese women candidates for sleeve gastrectomy during surgery 12 weeks post-intervention. mRNA levels will be quantified using real-time quantitative PCR (qRT-PCR).

    Time frame: 12 weeks after intervention

  6. C/EBP-alpha (CCAAT/enhancer-binding protein alpha) mRNA level in abdominal and subcutaneous adipose tissue

    Adipose tissue samples will be collected from obese women candidates for sleeve gastrectomy during surgery 12 weeks post-intervention. mRNA levels will be quantified using real-time quantitative PCR (qRT-PCR).

    Time frame: 12 weeks after intervention

  7. LXRα (Liver X Receptor alpha) mRNA levels in abdominal and subcutaneous adipose tissues

    Adipose tissue samples will be collected from obese women candidates for sleeve gastrectomy during surgery 12 weeks post-intervention. mRNA levels will be quantified using real-time quantitative PCR (qRT-PCR).

    Time frame: 12 weeks after intervention

Secondary outcomes

  1. Changes in fasting blood glucose

    Fasting blood glucose (FBS) levels will be measured in serum using standard laboratory methods after an overnight fast of at least 8 hours.Results will be reported in mg/dL.

    Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 and 6 months after surgery.

  2. Changes in fasting serum insulin

    Changes in fasting serum insulin levels will be measured using standard laboratory methods after an overnight fast of at least 8 hours. Results will be reported in IU/ml.

    Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 6 months after surgery.

  3. Changes in lipid profile

    Changes in lipid profile in serum, including total cholesterol (mg/dl), triglycerides , high-density lipoprotein cholesterol (HDL-C) (mg/dl), and low-density lipoprotein cholesterol (LDL-C) (mg/dl) will be measured using standard laboratory methods after an overnight fast of at least 8 hours. Results will be reported in mg/dl.

    Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.

  4. Changes in liver enzymes, including alanine aminotransferase (ALT), aspartate aminotransferase (AST)

    Alanine aminotransferase (ALT) (IU/ml), aspartate aminotransferase (AST)will be measured in serum using standard laboratory methods after an overnight fast of at least 8 hours. Results will be reported in IU/ml.

    Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.

  5. Changes in urea levels

    Serum urea concentrations will be measured using standard clinical laboratory methods. Results will be reported in mg/dL.

    Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.

  6. Changes in creatinine levels

    Serum creatinine concentrations will be measured using standard clinical laboratory methods. Results will be reported in mg/dL. Changes from baseline will be calculated at each follow-up assessment.

    Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.

  7. Change in Quality of Life

    Quality of life will be assessed using a validated, standardized questionnaire. Total scores will be calculated according to the instrument's scoring guidelines, with higher or lower scores interpreted according to the specific questionnaire used. Changes in quality-of-life scores will be calculated as the difference between the final assessment and baseline assessment.

    Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.

  8. Change in food addiction symptoms

    Food addiction symptoms will be assessed using the modified Yale Food Addiction Scale. Scores will be calculated according to the scale's scoring guidelines. Changes in food addiction symptom scores from baseline will be evaluated at each follow-up assessment.

    Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.

  9. Changes in Eating Behavior

    Eating behavior will be assessed using the study-specified eating behavior questionnaire. Questionnaire scores will be calculated according to the instrument's scoring guidelines. Changes in scores from baseline will be evaluated at each follow-up assessment.

    Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.

  10. Change in physical activity

    Physical activity will be assessed using a validated, standardized physical activity questionnaire. Changes in physical activity levels and scores from baseline will be evaluated at each follow-up assessment according to the questionnaire's scoring guidelines.

    Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.

  11. Changes in Body weight

    Body weight will be measured at baseline and at the end of the intervention using a calibrated digital scale, with participants wearing light clothing and no shoes. Weight reported in kilograms (kg).

    Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.

  12. Change in waist circumference

    Waist circumference will be measured in centimeters (cm) using a non-stretchable measuring tape according to standardized anthropometric procedures.

    Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.

  13. Change in hip circumference

    Hip circumference will be measured in centimeters (cm) using a non-stretchable measuring tape according to standardized anthropometric procedures.

    Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.

  14. Change in systolic and diastolic blood pressure

    Systolic and diastolic blood pressure will be measured in millimeters of mercury (mmHg) using a validated blood pressure monitor under standardized conditions.

    Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.

  15. Change in total body fat percentage

    Total body fat percentage will be assessed using bioelectrical impedance analysis (BIA) and expressed as a percentage (%).

    Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.

  16. Change in fat-free mass

    Fat-free mass will be assessed using bioelectrical impedance analysis (BIA) and expressed in kilograms (kg).

    Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.

  17. Change in muscle mass

    Muscle mass will be assessed using bioelectrical impedance analysis (BIA) and expressed in kilograms (kg).

    Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.

  18. Change in body mass index (BMI)

    Body mass index (BMI) will be calculated as body weight in kilograms divided by the square of height in meters (kg/m²). Height in meter will be measured at baseline for anthropometric characterization.Body weight and height will be measured using standardized procedures.

    Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.

07

Study locations

1 site
  • Department of Surgery, School of Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
    Tehran, 1417613151, Iran
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Sep 2027, 11 months after the start.

Of 3,690 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 11 months is below that.

Counting every sponsor, half of 3,853 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2026
First posted
Nov 17, 2026
StartActual
Oct 1, 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941050
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Oct 1, 2026
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion